Zsírmáj (MASLD/MASH): vizsgálatok itt: Németország

In Németország 23 Also abroad 366

23 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Berlin, Frankfurt am Main, Homburg, Leipzig, Lübeck, Mainz, Würzburg
Életkor
18 év to 80 év
People
1650 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06215716
3. fázisNot yet taking people in Németország
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
Where
Bad Homburg, Erlangen, Freiburg im Breisgau, Leipzig, Mainz
Életkor
18 év and over
People
600 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07850063 · EU 2026-527091-88-00
3. fázisTaking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Berlin, Bochum, Cologne, Dresden, Erlangen, Frankfurt Am Main, Heidelberg, Homburg, Landshut, Leipzig, Luebeck, Magdeburg, Mainz, Mannheim, Muenster, Tuebingen, Wiesbaden, Wuerzburg
Életkor
18 év and over
People
1800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
3. fázisTaking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Berlin, Bochum, Cologne, Dresden, Frankfurt Am Main, Heidelberg, Homburg, Landshut, Luebeck, Magdeburg, Mainz, Mannheim, Muenster, Wiesbaden, Wuerzburg
Életkor
18 év and over
People
1590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
3. fázisTaking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Where
Berlin, Hanover, Homburg, Leipzig, Luebeck
Életkor
18 év and over
People
205 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 · EU 2024-512895-36-00
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Chemnitz, Frankfurt Am Main, Freiburg im Breisgau, Hanover, Homburg, Muenster
Életkor
18 év to 80 év
People
1350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Chemnitz, Frankfurt Am Main, Freiburg im Breisgau, Hanover, Homburg, Muenster
Életkor
18 év to 75 év
People
1800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
No phaseTaking people
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
Where
Münster
Életkor
18 év and over
People
500
Run by
University Hospital Muenster
See details and how to joinNCT07877272
3. fázisNot yet taking people in Németország
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
Where
Berlin, Hamburg, Heidelberg, Homburg, Leipzig, Mainz, Muenster
Életkor
18 év and over
People
382 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00
3. fázisNot yet taking people in Németország
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
Where
Hamburg, Heidelberg, Homburg, Leipzig, Mainz, Muenster
Életkor
18 év and over
People
69 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00
3. fázisTaking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Berlin, Frankfurt am Main, Homburg, Leipzig, Lübeck
Életkor
18 év to 80 év
People
2150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
3. fázisTaking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Bad Oeynhausen, Berlin, Brandenburg, Dresden, Düsseldorf, Frankfurt, Hanover, Heidelberg, Homburg, Leipzig, Mainz, Neuruppin
Életkor
18 év and over
People
4500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
3. fázisTaking people
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Where
Berlin, Hamburg, Heidelberg, Homburg, Leipzig, Mainz, Muenster
Életkor
18 év to 75 év
People
1250 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00
No phaseTaking people
Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients With Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Placement
Where
Jena
Életkor
18 év to 99 év
People
80
Run by
Stephanie Gräger
See details and how to joinNCT06814990
No phaseTaking people
Identification of Liver Fibrosis Biomarkers
Where
Mainz
Életkor
18 év to 75 év
People
575 worldwide
Run by
Roche Diagnostics GmbH
See details and how to joinNCT06819917
No phaseTaking people
Time-restricted Feeding in MASLD
Where
Homburg
Életkor
18 év to 75 év
People
120
Run by
Universität des Saarlandes
See details and how to joinNCT07530809
3. fázisTaking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Berlin, Frankfurt Am Main, Homburg, Leipzig, Luebeck, Mainz, Wuerzburg
Életkor
18 év and over
People
244 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2023-505141-48-00 · EU 2023-505141-48-00
No phaseNot yet taking people in Németország
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
Where
Homburg
Életkor
18 év and over
People
30 000 worldwide
Run by
Universität des Saarlandes
See details and how to joinNCT06907563
No phaseTaking people
Global Research Initiative for Patients Screening on MASH
Where
Homburg, Mainz
Életkor
18 év to 75 év
People
10 000 worldwide
Run by
Julius Clinical
See details and how to joinNCT05651724
No phaseTaking people
Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases
Where
Dresden
Életkor
18 év and over
People
180
Run by
Technische Universität Dresden
See details and how to joinNCT06396871
No phaseCsak meghívásos
Prevalence of Advanced Fibrosis in Patients Living With HIV
Where
Mainz
Életkor
18 év and over
People
300
Run by
Johannes Gutenberg University Mainz
See details and how to joinNCT04066608
No phaseTaking people
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
Where
Düsseldorf
Életkor
18 év to 80 év
People
300
Run by
German Diabetes Center
See details and how to joinNCT05046483
No phaseTaking people
The European NAFLD Registry
Where
Aachen, Berlin, Freiburg im Breisgau, Mainz, Würzburg
Életkor
18 év to 100 év
People
10 000 worldwide
Run by
Newcastle University
See details and how to joinNCT04442334